提醒

Glaukos Corporation (GKOS)

NYSE: GKOS · 即時價格 · USD

179.87

-2.04 (-1.12%)

收盤價： Aug 28, 2026, 3:59 PM

179.87

+0.00%

盤後: 7:55 PM

股價、關鍵數字和最新消息，都在這一頁。

-1.12% (1D)

買價	160
市值	10.61B
營收 (ttm)	612.84M
淨利（ttm）	-188.05M
	0.76
	-3.24
	n/a
	356.65
P/B (ttm)	15.51
P/S (ttm)	17.31
財報日期	Oct 28, 2026

賣價	210
成交量	551,891
20 日平均成交量	888,600
開盤價	181.10
前收盤價	181.91
當日區間	177.77 - 182.22
52 週範圍	73.16 - 191.62
分析師	Strong Buy
目標價	195 (8.41%)
股利	n/a
除息日	n/a

關於 GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infi...

[閱讀更多]

產業 Medical Devices

類股 Healthcare

IPO 日期 Jun 25, 2015

員工 1,094

證券交易所 NYSE

股票代號 GKOS

網站 https://www.glaukos.com

完整的公司簡介

財務表現

Glaukos 在 2025 年的營收為 507.44M，較前一年的 383.48M 增加 32.33%。淨利為 -187.69M，較前期增加 28.23%。

財務報表

分析師預測

根據 13 位分析師的評等，GKOS 的平均評等為「Strong Buy」。12 個月目標價為 195，較最新價格有 8.41% 的上漲空間。

股票預測

財報驚奇

Glaukos 已於 Jul 29, 2026 公布季度財報：

營收為 $185.61M 低於預期 $0, 年增 49.54% 成長.
每股盈餘為 -0.14 超出預期 0.07, 年增 41.67% 成長.

下次財報發布

Glaukos Corporation 的下次財報預計於 Oct 28, 2026, 收盤後。
分析師預估營收 ... 升級

新聞動態

2 天前 · Zacks

Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

1 週前 · Zacks

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.

1 週前 · Zacks

Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

3 週前 · Motley Fool

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.

3 週前 · Zacks

Can da Vinci 5 Drive Intuitive Surgical's Next Multi-Year Upgrade Cycle?

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

第 1 頁，共 2 頁

Glaukos Corporation (GKOS)